Is BGM1812 legal in the United Kingdom?

A dual amylin and calcitonin receptor agonist from BrightGene, derived from the structure of petrelintide, with one medicinal chemistry paper reporting animal and in vitro results and two phase 1 trials recruiting in China and the United States. No human data have been published.

BGM1812 is a peptide developed by BrightGene Bio-Medical Technology in Suzhou, China, as a dual amylin and calcitonin receptor agonist (DACRA) for obesity. Its only publication is the discovery paper in the Journal of Medicinal Chemistry (July 2025), which describes it as the product of three rounds of structure-guided modification starting from petrelintide, the long-acting amylin analogue then in phase 2, using molecular dynamics simulations to compensate for the absence of structure-activity data.

Mechanism: Amylin receptors are formed from the calcitonin receptor together with receptor activity modifying proteins; a dual amylin and calcitonin receptor agonist activates both the amylin receptor complexes and the calcitonin receptor alone. In animals, DACRAs reduce food intake and body weight through hindbrain satiety circuits and slow gastric emptying, and the field's working hypothesis, reviewed in 2026, is that calcitonin receptor engagement may increase efficacy while also influencing nausea and aversion.

Regulatory history: Not approved. Two phase 1 trials (NCT07224399 in the United States, NCT07294235 in China) listed as recruiting with safety primary outcomes; no results posted; no human data published.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for BGM1812 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.